Abstract
The understanding of the signal transduction cascade involving growth factors and their receptors is one major key for diagnostic and therapeutic improvements in human neoplasms. Using receptor autoradiography, an inverse relationship for the incidence of somatostatin receptors (SSR) and epidermal growth factor receptors (EGFR) was found in gliomas [1]. In the majority of low grade gliomas, SSR were present but EGFR were absent. In contrast, EGFR were present in most glioblastomas, but no SSR were detected. Recently, the amplification of the EGFR gene and its overexpression was demonstrated to be associated with the development of glioblastomas. Several independent reports revealed that 40–50% of tumors show amplified EGFR [2–4]. The frequency of EGFR amplification was directly associated with tumor malignancy. In addition, amplified EGFR levels indicate a bad prognosis and shorter overall survival [5]. Recent analysis of the EGFR gene in tumors has shown that regions of this gene frequently undergo alteration. Hence, not only amplification but also mutation may be the cause of the increased malignancy in EGFR overexpressing cells [6].
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Reubi JC, Horisberger U, Lang W, Koper JW, Braakmann R, Lamberts SW: Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 134: 337–344, 1989
Liberman TA, Nusbaum HR, Razan N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144–147, 1985
Wong AJ, Bigner SH, Bigner D, Kinzler KW, Hamilton SR, Vogelstein B: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899–6903, 1987
Ekstrand AJ, James CD, Cavanee WK, Seliger B, Pettersson RF, Collins VP: Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomasin vivo. Cancer Res 51: 2164–2172, 1991
Jaros E, Perry RH, Adam L, Lelly PJ, Crawford PJ, Kalbay RM, Pearson ADJ: Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki67 labelling in brain tumors. Br J Cancer 66: 373–385, 1992
Akbasak A, Sunar-Akbasak B: Oncogenes: cause or consequence in the development of glial tumors. J Neurol Sci 111: 119–133, 1992
Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203–212, 1990
Carpenter G, Cohen S: Epidermal growth factor. J Biol Chem 265: 7709–7712, 1990
Pawson T, Gish GD: SH2 and SH3 domains: from structure to function. Cell 71: 359–362, 1992
Cadena DL, Gill GN: Receptor tyrosine kinases. FASEB J 6: 2332–2337, 1992
Marshall MS: The effector interactions of p21ras. TIBS 18: 250–254, 1993
Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D: The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 363: 85–88, 1993
Li N, Balzer A, Daly R, Yajnik V, Skolnik E, Chardin P, Bar-Sagi D, Margolis B, Schlessinger J: Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 363: 88–92, 1993
Gale NW, Kaplan S, Lowenstein EJ, Schlessinger J, Bar-Sagi D: Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature 363: 88–92, 1993
Winkler ME, O'Conner L, Winget M, Fendly B: Epidermal growth factor and transforming growth factor alpha bind differently to the epidermal growth factor receptor. Biochemistry 28: 6373–6378, 1989
Küng W, David F, Langen H, Weyer KA, Schlaeger E-J, Lahm H-W, Silber E, Mueller H, Eppenberger U: Isolation of mammamodulin, a heregulin-like growth factor secreted by estrogen receptor-negative MDA-MB-231 human breast cancer cells stimulating estrogen receptor-positive cells. Biochem Biophys Res Commun 202: 1357–1365, 1994
Orr-Urtreger A, Trokhtenbroth L, Ben-Levy R, Wen D, Rechavi G, Lonai P, Yarden Y: Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21. Proc Natl Acad Sci USA 90: 1867–1871, 1993
Falls DL, Rosen KM, Corfas G, Lane WS, Fishbach GD: ARIA, a protein that stimulates acetylcholine receptor synthesis is a member of the Neu ligand family. Cell 72: 8091–815, 1993
Marchionni MA, Goodearl ADJ, Chen MS, Bermingham-Mcdonogh O, Kirk C, Hendricks M, Danehy F, Misumi D, Baldassare M, Hiles I, Davis JB, Hsuan JJ, Totty NF, Otsu M, McBurney RN, Waterfield MD, Stoobant P, Gwynne D: Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362: 312–318, 1993
Brugge JS: New intracellular targets for therapeutic drug design. Science 260: 918–919, 1993
Mesri EA, Kreitman RJ, Fu YM, Epstein SE, Pastan I: Heparin-binding transforming growth factor alpha-Pseudomonas exotoxin A. A heparan sulfate-modulated recombinant toxin cytotoxic to cancer cells and proliferating smooth muscle cells. J Biol Chem 268: 4853–4862, 1993
Hynes NE, Marte BM, Hellmann P, Groner B, Wels W: Recombinant single chain immunotoxins specific for EGF and erbB2 receptors inhibitin vivo andin vitro tumor cell growth. J Cell Biochem 18D (Suppl): 237, 1994
Lamberts SW, Reubi JC, Krenning EP: Somatostatin receptor imaging in the diagnosis and treatment of neuroendocrine tumors. J Steroid Biochem Molec Biol 43: 185–188, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eppenberger, U., Mueller, H. Growth factor receptors and their ligands. J Neuro-Oncol 22, 249–254 (1994). https://doi.org/10.1007/BF01052929
Issue Date:
DOI: https://doi.org/10.1007/BF01052929